CVS recently made waves in the health industry with its purchase of health insurer Aetna Inc in November. The Company plans to introduce more health services into its stores to help fight chronic conditions. This plan was a huge factor in the acquisition of Aetna as it will help CVS to initiate this transition.
The Woonsocket, Rhode Island based Company reported that its pharmacy benefits unit brought in revenue of USD 34.84 Billion in the second quarter, a 4.2% increase from the same quarter of the prior year. Analysts had projected revenue of USD 34.2 Billion. CVS has been under pressure from the high dispensing rates of generic drugs but has enjoyed the benefits of higher prices on branded drugs.
The nation’s premier health innovation company reported earnings of USD 1.89 per share, surpassing the average analyst estimate of USD 1.69. CVS’s health insurance unit reported revenue of USD 17.4 Billion, also beating analyst estimates which came in at USD 17.3 Billion. Same store sales at the Company’s stores that sell over-the-counter drugs rose 2.9%, again surpassing analyst estimates of a 1.2% rise.
CVS reported net income of USD 1.94 Billion. This figure compares to a net loss of USD 2,56 Billion in the same quarter of the year prior.
President and Chief Executive Officer Larry Merlo stated, “We posted strong second quarter results, with all of our businesses performing at or above expectations. These results demonstrate our ability to execute on our strategic priorities to accelerate enterprise growth as we seek to fundamentally transform the consumer health experience. Given our performance to date and our expectations for the remainder of the year, we are raising and narrowing our Adjusted EPS guidance range to $6.89 to $7.00.”
52 week low/high
U.S. Judge Approves CVS-Aetna Merger0 Comments A federal judge on Wednesday formally approved the merger of CVS Health (NYSE: CVS) and U.S. health insurer Aetna, Inc. Judge Richard Leon of the U.S. District Court for the District of Columbia...
Amgen to Buy Celgene’s Otezla for $13.4 Billion0 Comments The American multinational biopharmaceutical company, Amgen (NASDAQ: AMGN) agreed to buy Celgene’s (NASDAQ: CELG) Otezla, which is a psoriasis treatment, for USD 13.4 Billion.The...
Pfizer to Merge Subsidiary with Mylan0 Comments Pfizer (NYSE: PFE) announced on Monday morning that its subsidiary, Upjohn will merge with Mylan (NASDAQ: MYL). Following the news, Mylan shares rose by 13% during Monday’s pre-market hours. Under...